{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:58:03Z","timestamp":1792627083440,"version":"4.5.0"},"reference-count":135,"publisher":"XMLink","issue":"4","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2023R1A2C2005297"],"award-info":[{"award-number":["NRF-2023R1A2C2005297"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["anndermatol.org"],"crossmark-restriction":false},"short-container-title":["Ann Dermatol"],"published-print":{"date-parts":[[2024]]},"DOI":"10.5021\/ad.24.038","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T06:51:05Z","timestamp":1718607065000},"page":"197","update-policy":"https:\/\/doi.org\/10.5021\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Up-and-Coming Drugs for the Treatment of Vitiligo"],"prefix":"10.5021","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6965-3515","authenticated-orcid":false,"given":"Seol Hwa","family":"Seong","sequence":"first","affiliation":[{"name":"Department of Dermatology, Kosin University College of Medicine, Busan, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4477-1400","authenticated-orcid":false,"given":"Sang Ho","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18617","reference":[{"key":"10.5021\/ad.24.038_ref1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.5021\/ad.24.038_ref2","doi-asserted-by":"crossref","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.5021\/ad.24.038_ref3","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"Kr\u00fcger","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.5021\/ad.24.038_ref4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3349\/ymj.2015.56.3.719","volume":"56","author":"Lee","year":"2015","journal-title":"Yonsei Med J"},{"key":"10.5021\/ad.24.038_ref5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.5021\/ad.24.038_ref6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.5021\/ad.24.038_ref7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0378-6323.32708","volume":"73","author":"Sehgal","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.5021\/ad.24.038_ref8","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/jdv.19450","volume":"37","author":"Seneschal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.5021\/ad.24.038_ref9","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/jdv.19451","volume":"37","author":"van Geel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.5021\/ad.24.038_ref10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.coi.2013.10.010","volume":"25","author":"Richmond","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.5021\/ad.24.038_ref11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11010-011-0752-2","volume":"352","author":"Thulasingam","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.5021\/ad.24.038_ref12","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jid.2019.12.035","volume":"140","author":"Ahn","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref13","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/bjd.15151","volume":"176","author":"Kim","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.5021\/ad.24.038_ref14","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.jid.2019.03.1148","volume":"139","author":"Cui","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2015.09.003","volume":"81","author":"Xie","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.5021\/ad.24.038_ref16","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/s41467-019-09963-8","volume":"10","author":"Tulic","year":"2019","journal-title":"Nat Commun"},{"key":"10.5021\/ad.24.038_ref17","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","volume":"132","author":"Harris","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jid.2018.10.032","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref19","doi-asserted-by":"crossref","first-page":"eaam7710","DOI":"10.1126\/scitranslmed.aam7710","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.5021\/ad.24.038_ref20","first-page":"e133772","volume":"5","author":"Boukhedouni","year":"2020","journal-title":"JCI Insight"},{"key":"10.5021\/ad.24.038_ref21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.autrev.2014.10.002","volume":"14","author":"Dwivedi","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.5021\/ad.24.038_ref22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jid.2023.08.006","volume":"144","author":"Lee","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5021\/ad.23.065","volume":"35","author":"Tanemura","year":"2023","journal-title":"Ann Dermatol"},{"key":"10.5021\/ad.24.038_ref24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","volume":"194","author":"Villarino","year":"2015","journal-title":"J Immunol"},{"key":"10.5021\/ad.24.038_ref25","first-page":"343","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.5021\/ad.24.038_ref26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.5021\/ad.24.038_ref27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2019.05.011","volume":"139","author":"Chen","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"10.5021\/ad.24.038_ref28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/bjd.15550","volume":"177","author":"Jacquemin","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.5021\/ad.24.038_ref29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41586-021-04221-8","volume":"601","author":"Xu","year":"2022","journal-title":"Nature"},{"key":"10.5021\/ad.24.038_ref30","first-page":"394","volume":"13","author":"Mesa","year":"2010","journal-title":"IDrugs"},{"key":"10.5021\/ad.24.038_ref31","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.5021\/ad.24.038_ref32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.5021\/ad.24.038_ref33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.5021\/ad.24.038_ref34","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement_2","key":"10.5021\/ad.24.038_ref35","doi-asserted-by":"crossref","first-page":"ii66","DOI":"10.1093\/bjd\/ljad498.067","volume":"190","author":"Wolkerstorfer","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.5021\/ad.24.038_ref36","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1016\/j.jid.2022.05.1093","volume":"142","author":"Pandya","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref37","unstructured":"Incyte Corporation. A study to evaluate the safety and efficacy of ruxolitinib cream with phototherapy in participants with vitiligo [Internet]. 2022. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05247489"},{"key":"10.5021\/ad.24.038_ref38","unstructured":"Incyte Corporation. A study to assess the safety and efficacy of ruxolitinib cream in participants with genital vitiligo [Internet]. 2023. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05750823"},{"key":"10.5021\/ad.24.038_ref39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"Harrington","year":"2020","journal-title":"J Inflamm Res"},{"key":"10.5021\/ad.24.038_ref40","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.5021\/ad.24.038_ref41","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.5021\/ad.24.038_ref42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jid.2020.04.027","volume":"141","author":"Azzolino","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","volume":"81","author":"McKesey","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.5021\/ad.24.038_ref44","unstructured":"Pi Research Consultancy Center (BD). Role of tofacitinib in vitiligo patients (ETV) [Internet]. 2022. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05293119"},{"key":"10.5021\/ad.24.038_ref45","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/JIR.S356316","volume":"15","author":"Zhang","year":"2022","journal-title":"J Inflamm Res"},{"key":"10.5021\/ad.24.038_ref46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ajd.13348","volume":"61","author":"Mumford","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.5021\/ad.24.038_ref47","doi-asserted-by":"crossref","first-page":"15593258221105370","DOI":"10.1177\/15593258221105370","volume":"20","author":"Dong","year":"2022","journal-title":"Dose Response"},{"key":"10.5021\/ad.24.038_ref48","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1159\/000518541","volume":"238","author":"Li","year":"2022","journal-title":"Dermatology"},{"key":"10.5021\/ad.24.038_ref49","unstructured":"University Hospital, Bordeaux. Evaluation of effect and tolerance of the association of baricitinib and phototherapy versus phototherapy in adults with progressive vitiligo [Internet]. 2021. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT04822584"},{"key":"10.5021\/ad.24.038_ref50","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.jaad.2023.07.1016","volume":"89","author":"Su","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.5021\/ad.24.038_ref51","doi-asserted-by":"crossref","first-page":"2200873","DOI":"10.1080\/09546634.2023.2200873","volume":"34","author":"Pan","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"Supplement_2","key":"10.5021\/ad.24.038_ref52","doi-asserted-by":"crossref","first-page":"ii64","DOI":"10.1093\/bjd\/ljad498.065","volume":"190","author":"Ezzedine","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.5021\/ad.24.038_ref53","unstructured":"AbbVie. A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo [Internet]. 2023. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT06118411"},{"key":"10.5021\/ad.24.038_ref54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.5021\/ad.24.038_ref55","doi-asserted-by":"crossref","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.5021\/ad.24.038_ref56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/1346-8138.17064","volume":"51","author":"Dainichi","year":"2024","journal-title":"J Dermatol"},{"key":"10.5021\/ad.24.038_ref57","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"10.5021\/ad.24.038_ref58","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/ni.2744","volume":"14","author":"Mackay","year":"2013","journal-title":"Nat Immunol"},{"key":"10.5021\/ad.24.038_ref59","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.5021\/ad.24.038_ref60","unstructured":"Pfizer. A 52-week study of ritlecitinib oral capsules in adults and adolescents with nonsegmental vitiligo (active and stable) tranquillo [Internet]. 2022. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05583526"},{"key":"10.5021\/ad.24.038_ref61","unstructured":"Aclaris Therapeutics, Inc. A study of ATI-50002 topical solution for the treatment of vitiligo [Internet]. 2018. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT03468855"},{"key":"10.5021\/ad.24.038_ref62","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/ajd.13572","volume":"62","author":"Yagi","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.5021\/ad.24.038_ref63","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1684\/ejd.2023.4513","volume":"33","author":"Murakami","year":"2023","journal-title":"Eur J Dermatol"},{"key":"10.5021\/ad.24.038_ref64","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"10.5021\/ad.24.038_ref65","unstructured":"Pfizer. A phase 2b study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in active non-segmental vitiligo subjects [Internet]. 2018. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT03715829"},{"key":"10.5021\/ad.24.038_ref66","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","volume":"90","author":"Kirby","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.5021\/ad.24.038_ref67","unstructured":"Incyte Corporation. A study to evaluate efficacy and safety of povorcitinib in participants with nonsegmental vitiligo (STOP-V1) [Internet]. 2023. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT06113445"},{"key":"10.5021\/ad.24.038_ref68","unstructured":"Incyte Corporation. A study to evaluate efficacy and safety of povorcitinib in participants with nonsegmental vitiligo (STOP-V2) [Internet]. 2023. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT06113471"},{"key":"10.5021\/ad.24.038_ref69","unstructured":"Incyte Corporation. A study to evaluate the efficacy and safety of INCB054707 in participants with vitiligo [Internet]. 2021. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT04818346"},{"key":"10.5021\/ad.24.038_ref70","unstructured":"Arcutis Biotherapeutics, Inc. Safety and efficacy of ARQ-252 cream 0.3% in subjects with non-segmental facial vitiligo [Internet]. 2021. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT04811131"},{"key":"10.5021\/ad.24.038_ref71","unstructured":"Reistone Biopharma Company Limited. Assess the efficacy and safety of SHR0302 ointment in adult patients with vitiligo [Internet]. 2020. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT04774809"},{"key":"10.5021\/ad.24.038_ref72","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","volume":"89","author":"Zhou","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.5021\/ad.24.038_ref73","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","volume":"135","author":"Cavali\u00e9","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1755-148X.2011.00916.x","volume":"25","author":"Mosenson","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.5021\/ad.24.038_ref75","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/BOR.0000000000001003","volume":"36","author":"Kato","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"10.5021\/ad.24.038_ref76","unstructured":"University Hospital, Bordeaux; AstraZeneca. Efficacy and tolerance of the association of anifrolumab (300 mg) IV every four weeks and phototherapy versus phototherapy in adults with progressive vitiligo [Internet]. 2023. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05917561"},{"key":"10.5021\/ad.24.038_ref77","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcmr.12219","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.5021\/ad.24.038_ref78","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/pcmr.12935","volume":"34","author":"Riding","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.5021\/ad.24.038_ref79","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jocd.13908","volume":"20","author":"Atwa","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"10.5021\/ad.24.038_ref80","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","volume":"4","author":"Cellier","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.5021\/ad.24.038_ref81","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). Evaluation of AMG 714 for vitiligo (REVEAL) [Internet]. 2020. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT04338581"},{"key":"10.5021\/ad.24.038_ref82","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jgg.2011.05.005","volume":"38","author":"Spritz","year":"2011","journal-title":"J Genet Genomics"},{"key":"10.5021\/ad.24.038_ref83","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.4049\/jimmunol.1900733","volume":"203","author":"Tahvildari","year":"2019","journal-title":"J Immunol"},{"key":"10.5021\/ad.24.038_ref84","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","volume":"24","author":"Lykhopiy","year":"2023","journal-title":"Genes Immun"},{"key":"10.5021\/ad.24.038_ref85","unstructured":"Merck Sharp & Dohme LLC. A clinical study of MK-6194 for the treatment of vitiligo (MK-6194-007) [Internet]. 2023. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT06113328"},{"key":"10.5021\/ad.24.038_ref86","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/exd.13069","volume":"26","author":"Speeckaert","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.5021\/ad.24.038_ref87","first-page":"CD007277","volume":"2009","author":"Maxwell","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.5021\/ad.24.038_ref88","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/pcmr.12105","volume":"26","author":"Dwivedi","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.5021\/ad.24.038_ref89","unstructured":"Brigham and Women's Hospital. Open-label pilot study of abatacept for the treatment of vitiligo [Internet]. 2015. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT02281058"},{"key":"10.5021\/ad.24.038_ref90","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.5021\/ad.24.038_ref91","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/15548627.2018.1531197","volume":"15","author":"Ozturk","year":"2019","journal-title":"Autophagy"},{"key":"10.5021\/ad.24.038_ref92","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.3390\/ijms21176129","volume":"21","author":"Hida","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.5021\/ad.24.038_ref93","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.2174\/0929867324666170530093902","volume":"24","author":"Sakkas","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.5021\/ad.24.038_ref94","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jid.2019.11.031","volume":"140","author":"Khemis","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref95","first-page":"e37180","volume":"15","author":"Sharma","year":"2023","journal-title":"Cureus"},{"key":"10.5021\/ad.24.038_ref96","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jaad.2020.12.073","volume":"85","author":"Kim","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.5021\/ad.24.038_ref97","doi-asserted-by":"crossref","first-page":"e12923","DOI":"10.1111\/dth.12923","volume":"32","author":"Majid","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.5021\/ad.24.038_ref98","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00403-022-02343-1","volume":"315","author":"Kim","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.5021\/ad.24.038_ref99","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2021.03.028","volume":"11","author":"Tam","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.5021\/ad.24.038_ref100","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/bjd\/ljac092","volume":"188","author":"Sun","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.5021\/ad.24.038_ref101","unstructured":"University of Colorado, Denver. Study of efficacy, safety and tolerability of crisaborole and PF-07038124 with and without NBUVB in vitiligo [Internet]. 2022. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05298033"},{"key":"10.5021\/ad.24.038_ref102","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","volume":"373","author":"Langendonk","year":"2015","journal-title":"N Engl J Med"},{"key":"10.5021\/ad.24.038_ref103","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-016-0501-5","volume":"56","author":"Minder","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.5021\/ad.24.038_ref104","first-page":"775","volume":"12","author":"Fabrikant","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.5021\/ad.24.038_ref105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/2013.jamadermatol.386","volume":"149","author":"Grimes","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.5021\/ad.24.038_ref106","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.5021\/ad.24.038_ref107","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaad.2020.01.035","volume":"82","author":"Toh","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.5021\/ad.24.038_ref108","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamadermatol.2014.4848","volume":"151","author":"Passeron","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.5021\/ad.24.038_ref109","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamadermatol.2014.4951","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.5021\/ad.24.038_ref110","unstructured":"Clinuvel. Inc. A study to assess the changes in pigmentation and safety of afamelanotide in patients with vitiligo on the face [Internet]. 2022. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05210582"},{"key":"10.5021\/ad.24.038_ref111","unstructured":"Clinuvel, Inc. A study to compare the efficacy and safety of SCENESSE and narrow-band ultraviolet (NB-UVB) light versus NB-UVB light alone in patients with vitiligo [Internet]. 2023. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT06109649"},{"key":"10.5021\/ad.24.038_ref112","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1001\/archopht.123.11.1609","volume":"123","author":"Galloway","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.5021\/ad.24.038_ref113","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1600-0749.2000.130305.x","volume":"13","author":"Prota","year":"2000","journal-title":"Pigment Cell Res"},{"key":"10.5021\/ad.24.038_ref114","doi-asserted-by":"crossref","first-page":"e13175","DOI":"10.1111\/dth.13175","volume":"33","author":"Nowroozpoor Dailami","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.5021\/ad.24.038_ref115","first-page":"e14813","volume":"34","author":"Neinaa","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.5021\/ad.24.038_ref116","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1038\/s41598-023-32591-8","volume":"13","author":"Silpa-Archa","year":"2023","journal-title":"Sci Rep"},{"key":"10.5021\/ad.24.038_ref117","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/jocd.13648","volume":"20","author":"Kanokrungsee","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"10.5021\/ad.24.038_ref118","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/ijd.16307","volume":"61","author":"Nagui","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.5021\/ad.24.038_ref119","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41419-021-03592-0","volume":"12","author":"Bastonini","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.5021\/ad.24.038_ref120","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.5021\/ad.24.038_ref121","first-page":"2064","volume":"96","author":"Nie","year":"2016","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.5021\/ad.24.038_ref122","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"10.5021\/ad.24.038_ref123","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/jid.2013.540","volume":"134","author":"Chatterjee","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref124","unstructured":"Medical University of South Carolina. Daily topical rapamycin for vitiligo [Internet]. 2022. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05342519"},{"key":"10.5021\/ad.24.038_ref125","unstructured":"University of Massachusetts, Worcester. Evaluating the efficacy and safety of metformin in vitiligo [Internet]. 2023. cited 2024 February 28. Available from: https:\/\/classic.clinicaltrials.gov\/show\/NCT05607316"},{"key":"10.5021\/ad.24.038_ref126","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3389\/fimmu.2018.01236","volume":"9","author":"Ursini","year":"2018","journal-title":"Front Immunol"},{"key":"10.5021\/ad.24.038_ref127","first-page":"422","volume-title":"P099: An identification of potential therapeutics for vitiligo by mass screening for 1732 medicines in Korean National Health Insurance database","author":"Lee","year":"2020"},{"key":"10.5021\/ad.24.038_ref128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.04.005","volume":"38","author":"Pearce","year":"2013","journal-title":"Immunity"},{"key":"10.5021\/ad.24.038_ref129","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature11862","volume":"493","author":"O\u2019Neill","year":"2013","journal-title":"Nature"},{"key":"10.5021\/ad.24.038_ref130","doi-asserted-by":"crossref","first-page":"274ra18","DOI":"10.1126\/scitranslmed.aaa0835","volume":"7","author":"Yin","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.5021\/ad.24.038_ref131","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.0022-202X.2005.10130_6.x","volume":"10","author":"Skurkovich","year":"2005","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.5021\/ad.24.038_ref132","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.5021\/ad.24.038_ref133","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jid.2016.10.048","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.5021\/ad.24.038_ref134","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/jdv.19022","volume":"37","author":"Lin","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.5021\/ad.24.038_ref135","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/s41374-018-0126-4","volume":"98","author":"Tang","year":"2018","journal-title":"Lab Invest"}],"container-title":["Annals of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/anndermatol.org\/pdf\/10.5021\/ad.24.038","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/anndermatol.org\/DOIx.php?id=10.5021\/ad.24.038","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/anndermatol.org\/DOIx.php?id=10.5021\/ad.24.038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T05:37:24Z","timestamp":1721799444000},"score":1,"resource":{"primary":{"URL":"https:\/\/anndermatol.org\/DOIx.php?id=10.5021\/ad.24.038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":135,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5021\/ad.24.038","relation":{},"ISSN":["1013-9087","2005-3894"],"issn-type":[{"value":"1013-9087","type":"print"},{"value":"2005-3894","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"2024-03-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-07","name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-10","name":"published_online","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"\u00a9 2024 The Korean Dermatological Association and The Korean Society for Investigative Dermatology","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","explanation":{"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}]}}